Clozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 11, 2011, Pages 968-975

  Xiang, Yu Tao ^a   Wang, Chuan Yue ^b   Si, Tian Mei ^c   Lee, Edwin H M ^a   He, Yan Ling ^d   Ungvari, Gabor S ^e   Chiu, Helen F K ^a   Shinfuku, Naotaka ^f   Yang, Shu Yu ^g,h   Chong, Mian Yoon ⁱ   Kua, Ee Heok ^j   Fujii, Senta ^k   Sim, Kang ^l   Yong, Michael K H ^l   Trivedi, Jitendra K ^m   Chung, Eun Kee ⁿ   Udomratn, Pichet ^o   Chee, Kok Yoon ^p   Sartorius, Norman ^q   Dixon, Lisa B ^r,s   Kreyenbuhl, Julie A ^a   Tan, Chay Hoon ^j   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f SEINAN GAKUIN UNIVERSITY   (Japan)

^g TAIPEI CITY HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY   (Taiwan)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k Hyogo Institute for Traumatic Stress HITS   (Japan)

^l INSTITUTE OF MENTAL HEALTH   (Singapore)

^m KING GEORGE'S MEDICAL UNIVERSITY   (India)

ⁿ Seoul National University   (South Korea)

^o PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^p HOSPITAL KUALA LUMPUR   (Malaysia)

^q Association for the Improvement of Mental Health Programs   (Switzerland)

^r UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^s VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Clozapine; Prescription patterns; Schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GROUPS BY AGE AND SEX; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEGATIVE SYNDROME; PHARMACOEPIDEMIOLOGY; POSITIVE SYNDROME; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOCIOECONOMICS; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ASIA; CLOZAPINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA;

EID: 80555145990     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2011.607426     Document Type: Review

References (27)

1. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I. Clozapine and agranulocytosis [letter]. Lancet 1975; 2:611.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796.
3. Drew LR. Controls on clozapine must be reviewed. Aust N Z J Psychiatry 2010; 44:490.
4. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: A clinical review of adverse effects and management. Ann Clin Psychiatry 2003; 15:33-48.
5. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91.
6. Puri BK, Taylor DG, Alcock ME. Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. Br J Clin Pract 1995; 49:333-334.
7. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411-417.
8. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Lowdose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59:103-107.
9. O'Brien A. Starting clozapine in the community: A UK perspective. CNS Drugs 2004; 18:845-852.
10. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24:381-390.
11. Si TM, Shu L, Yu X et al. Antipsychotic drug patterns of schizophrenia in China: A cross-sectional study [in Chinese]. Chin J Psychiatry 2004; 37:152-155.
12. Liu TL, Li CY. The comparison of use of antipsychotics in first-episode patients with schizophrenia [in Chinese]. Med J Chin People Health 2003; 15:289-290.
13. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum Psychopharmacol 2007; 22:17-25.
14. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia OutpatienThealth Outcome) study: Implications for the treatment of schizophrenia. CNS Drugs 2006; 20:293-301.
15. APA. Practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Press, 1997.
16. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacolology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8:55-66.
17. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-667.
18. Chinese Medical Association. Guideline for the prevention and treatment of schizophrenia in China. Beijing: Chinese Medical Association, 2003.
19. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-999.
20. Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005; 60:759-764.
21. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42:607-618.
22. Malalagama G, Bastiampillai T, Dhillon R. Clozapine prescription patterns in Australia over the last 10 years. Aust N Z J Psychiatry 2011; 45:498-499.
23. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: Another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152: 827-832.
24. Wheeler A, Humberstone V, Robinson E. Ethnic comparisons of antipsychotic use in schizophrenia. Aust N Z J Psychiatry 2008; 42:863-873.
25. Young CR, Longhurst JG, Bowers MB Jr, Mazure CM. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997; 5:216-234.
26. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: A review on effi cacy and side effects. Curr Chemistry 2004; 11:343-358.
27. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 2001; 24:59-73.